Bengaluru :: Vertex Pharmaceuticals missed Wall Street’s estimate for quarterly results on Monday due to less than the sales of its cystic fibrosis (CF) drug trichefts.
However, the drugmaker raised the lower end of its income forecast as it looks at its acute pain medication, Journey X QS and new CF drugs to move its installed treatment line.
In December, the US The Food and Drug Administration allowed the alifutrac, the treatment of the upcoming pay generation of Vertex. This one -time treatment of a rare and progressive genetic disease strengthens the vertex market dominance in CF treatment.
CF is a hereditary disorder that results from the absence of a certain protein, which disrupts salt and water movements inside and outside the cells in various organs.
In the first quarter ended March 31, the company’s old CF treatment increased by 2% to $ 2.53 billion, but according to LSEG data, the average expectation of analysts is $ 2.58 billion.
Vertex has activated more than 65 authorized treatment centers globally and 90 patients have launched a cell collection for its gene therapy Casgavi, which treats a rare blood disorder in which regular blood can be operated.
Vertex, 2025, looks between $ 11.85 billion and $ 12 billion, compared to $ 11.75 billion to $ 12 billion compared to the previous estimated range.
Total quarterly revenue increased 2.7% to $ 2.77 billion, estimated at $ 2.85 billion of analysts.
On a adjusted basis, the company recorded a profit of 6 4.06 per share in the quarter, while analysts expected 32 4.32 profits.
(Reported by Sriparna Roy and Christie Santosh in Bengaluru; edit by Mohammad Safi Shamsi)
